Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for antibody-drug conjugates.

Septerna, Inc. (NASDAQ:SEPN) is one of the best up and coming stocks on our list. TheFly reported on June 11 that Guggenheim ...

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

Novartis AG NVS has agreed to acquire privately held U.K. biotechnology company Myricx Bio in a deal valued at up to $1.5 ...

Discover Prague's biotech hub, now viewed as the primary ‘entry gateway’ into the wider Central and Eastern European ...

Study demonstrates application of DNA-Encoded Library screening to native-like membrane protein targets with the ...

PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class ...

ADC payload with a differentiated mechanism of actionCombines oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumour ...

Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to ...

Talawar Therapeutics and JATT II enter definitive business combination agreement to create publicly listed biotechnology company: New York Wednesday, July 1, 2026, 16:00 Hrs [IST] ...

While multinational pharmaceutical companies use India to test out their new medicines, India’s researchers rarely lead the ...

INTENT Biologics, a clinical-stage biotechnology company developing first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the ...